Value in Health
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
The Associations of Prescription Drug Insurance and Cost-Sharing With Drug Use, Health Services Use, and Health: A Systematic Review of Canadian Studies
2023
-
ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY
2022
-
CLINICAL OUTCOMES OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WITH OR WITHOUT SARCOMATOID DIFFERENTIATION TREATED WITH SYSTEMIC THERAPY IN REAL-WORLD CANADIAN SETTING
2022
-
DEVELOPMENT AND APPLICATION OF A NEW COST-UTILITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN MODERATE-TO-LATE PRETERM INFANTS
2022
-
PRACTICAL CONSIDERATIONS FOR DEVELOPING PICO STATEMENTS FOR HUMANISTIC BURDEN REVIEWS: HOW TO GET IT RIGHT
2022
-
RESOURCE USE AND COSTS ASSOCIATED WITH COMPUTERIZED DECISION SUPPORT SYSTEM FOR MANAGING PATIENTS WITH ATRIAL FIBRILLATION
2022
-
TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG GENERALIZED PUSTULAR PSORIASIS PATIENTS: A CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS
2022
-
TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG PALMOPLANTAR PUSTOLOSIS PATIENTS: A 10-YEAR CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS
2022
-
Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics
2022
-
COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
2022
-
IMPACT OF DEPRESSION RELAPSE ON PARTICIPANT QUALITY OF LIFE AND COSTS TO THE ENGLISH NHS: SECONDARY ANALYSIS FROM THE ANTLER STUDY ON ANTIDEPRESSANT DISCONTINUATION IN WELL PATIENTS IN PRIMARY CARE
2022
-
THE IMPACT OF KEY HEALTH STATE TRANSITIONS ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN DUCHENNE MUSCULAR DYSTROPHY (DMD): A QUALITATIVE STUDY
2022
-
TIME TRADE-OFF UTILITY VALUES FOR HEALTH STATES CHARACTERIZING PROGRESSIVE MUSCULAR DEGENERATION IN DUCHENNE MUSCULAR DYSTROPHY (DMD)
2022
-
ECONOMIC COST OF IN CANADA: A MULTI-CENTRE, RETROSPECTIVE STUDY
2022
-
PLATFORM TRIALS: A PATH TO EFFICIENT DECISION MAKING AND FASTER DRUG APPROVALS FOR HEALTH TECHNOLOGY ASSESSMENT BODIES
2022
-
SYSTEMATIC REVIEW OF PROBABILISTIC SENSITIVITY ANALYSIS METHODS IN MICROSIMULATION OF CHRONIC DISEASES
2022
-
THE DRIVERS OF HEALTH STATE UTILITIES IN DUCHENNE MUSCULAR DYSTROPHY (DMD): A STUDY USING THE HEALTH UTILITIES INDEX MARK 3 (HUI3)
2021
-
WHAT IS VALUE? A SYSTEMATIC REVIEW OF VALUE ASSESSMENT FRAMEWORKS
2021
-
IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT)
2020
-
COST-EFFECTIVENESS OF RIVAROXABAN IN THE TREATMENT OF PATIENTS WITH CHRONIC CAD OR PAD IN THE UK
2019
-
ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS
2019
-
UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW
2019
-
PCN41 THE HEALTH UTILITY BOOK (HUB): A REGISTRY OF HEALTH STATE UTILITY VALUES IN ONCOLOGY
2019
-
PCN42 THE HEALTH UTILITY BOOK (HUB): TOWARD A CENTRALIZED, SYSTEMATIC APPROACH TO THE IDENTIFICATION, APPRAISAL, AND USE OF HEALTH STATE UTILITY VALUES FOR REIMBURSEMENT DECISION MAKING
2019
-
PNS88 IMPACT OF PATIENT-TARGETED FINANCIAL INCENTIVES ON HEALTHCARE COSTS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
2019
-
ASSESSING THE IMPACT OF ACTIVE IDENTIFICATION OF PATIENTS APPROPRIATE FOR PALLIATIVE CARE ON RESOURCE UTILIZATION AND COSTS IN THE FINAL MONTH OF LIFE
2018
-
PMS32 - ASSESSING DIRECT AND INDIRECT HEALTH SYSTEM COSTS OF THE BUILD BETTER BONES WITH EXERCISE PILOT TRIAL
2018
-
Budget Impact of Adding a New Single Inhaler Triple Therapy (SITT) for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) in the UK
2018
-
Cost-Effectiveness of a Single Inhaler Triple Therapy vs a Dual Inhaled Corticosteroid Plus Long-Acting Beta Agonist (ICS/LABA) for Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United Kingdom (UK)
2018
-
Cost-Minimization Analysis of Adding a New Single Inhaler Triple Therapy (SITT) for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (Copd) in the UK
2018
-
Economic Consequences of Clinically Important Deterioration in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the Torch Study
2018
-
Evidence Driven Cancer Drug Approvals In Phase II Versus Phase III Clinical Trials Within A Single-Payer Public Healthcare System
2018
-
First Steps in Choosing Appropriate Instruments/Measurements for a Core Outcome Set: An Example from Corehem
2018
-
How Values Inform the Health Policy Decision-Making Processes About Health-System Financing in Latin America? A Critical Interpretive Synthesis
2018
-
Respiratory Illness (RI) and Respiratory Syncytial Virus (RSV)-Related Hospitalization (RSVH) in Infants with Congenital Diaphragmatic Hernia (CDH) in the Caress Registry (2005-2017)
2018
-
United States Valuation of EQ-5D-5L Health States: An Initial Model Using a Standardized Protocol
2018
-
Development of A New Patient-Reported Outcome Instrument To Evaluate Treatments For Stretchmarks: The Body-Q Stretchmark Scale
2017
-
Economic Evaluation of Single Inhaler Triple Therapy For Patients With Chronic Obstructive Pulmonary Disease (COPD) Using The Galaxy Model
2017
-
Estimating the Comparative Accuracy of Diagnostic Tests: AN Example using Typhoid Fever
2017
-
Health and Economic Benefits of Using Single Versus Multiple Inhalers in Patients with Asthma: A Systematic Literature Review
2017
-
Optimal Usage of Sacubitril/Valsartan For Heart Failure Treatment In Canada Potentially Reduces Mortality, Hospitalizations And Early Discharge Re-Admissions
2017
-
Reliability, Validity and Responsiveness of A New Measure of Neck Disability (ND10)
2017
-
Single Versus Multiple Inhalers in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
2017
-
Translation And Cultural Adaptation Of The Body-Q Chest Module Into Finnish For Use In Gynecomastia, Weight Loss And FTM Chest Surgery
2017
-
A META-EPIDEMIOLOGICAL SURVEY OF THE REPORTING OF EFFECT MODIFICATION IN NETWORK META-ANALYSES
2017
-
CONSIDERATIONS IN THE ECONOMIC EVALUATION OF NURSE PRACTITIONERS AND CLINICAL NURSE SPECIALISTS ROLES
2017
-
COST-EFFECTIVENESS ANALYSES OF UMECLIDINIUM BROMIDE 62.5 MCG VERSUS GLYCOPYRRONIUM 44 MCG AND UMECLIDINIUM BROMIDE 62.5 MCG VERSUS TIOTROPIUM 18 MCG IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UK
2017
-
COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN PSORIATIC ARTHRITIS: A CANADIAN PERSPECTIVE
2017
-
RESPIRATORY ILLNESS AND RESPIRATORY SYNCYTIAL VIRUS (RSV)-RELATED HOSPITALIZATION (RSVH) IN INFANTS WITH CONGENITAL AIRWAY ANOMALIES (CAA) IN THE CARESS REGISTRY (2005-2016)
2017
-
ROBOTIC-ASSISTED THORACOSCOPIC PULMONARY RESECTION VERSUS VIDEO-ASSISTED THORACOSCOPIC PULMONARY RESECTION FOR EARLY STAGE NON-SMALL CELL LUNG CANCER: A HEALTHCARE UTILIZATION ANALYSIS
2017
-
Factors Influencing Door-To-Doctor Time In An Emergency Department: Discrete Event Simulation Model
2016
-
Linguistic Validation of the Finnish Version of the Body-Q Pro Instrument
2016
-
NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY AND SAFETY OF LINAGLIPTIN, EMPAGLIFLOZIN AND THE FIXED DOSE COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
2016
-
Comparison Of First- And Second-Season Palivizumab Prophylaxis In Patients With Congenital Airway Anomalies (Caa) In The Caress Database (2005-2015)
2016
-
Dalteparin Versus Vitamin K Antagonists for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer and Renal Impairment: Pharmacoeconomic Analysis of a Prospective Randomized Trial
2016
-
Indirect Costs Associated with Cardiovascular Disease in Canada: A Literature Review
2016
-
NURSE-LED CARE FOR PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW
2016
-
Trends In Oral Glucocorticoid Utilization Among Older Adults With Respiratory Disease
2016
-
Propensity Score Matching Does not Always Remove Confounding within an Economic Evaluation Based on a Non-Randomized Study
2015
-
The Cost-Effectiveness of Referring Patients With Irritable Bowel Syndrome To A Gastroenterologist In The Uk
2015
-
A review of health-related quality of life (hrql) claims in labels of asthma products – can we consider the asthma quality of life questionnaire (aqlq) as a potentially acceptable measure for qualification?
2015
-
Assure-Csu Canadian Results: Assessing Health Utility In Chronic Spontaneous/Idiopathic Urticaria Using The Eq-5d
2015
-
Comparing First- and Second-Season Palivizumab Prophylaxis In Patients with Hemodynamically Significant Congenital Heart Disease in the Caress Database (2005-2014)
2015
-
Respiratory Related Hospitalizations In Premature Infants Prophylaxed With Palivizumab In the Canadian Registry of Palivizumab (Caress)
2015
-
Serious Adverse Events In Canadian Children Receiving Palivizumab for the Prevention of Respiratory Syncytial Virus Infection
2015
-
The Economic Value of Tofacitinib 5 Mg Bid In The Treatment of Moderate To Severe Rheumatoid Arthritis: A Canadian Analysis
2015
-
The Processes For A Common Quality Assurance Approach To Multi-Centre Clinical Trials – The Mars Excite Experience
2015
-
Usability Testing Of The Web-Based Versions Of The Standardised Asthma Quality Of Life Questionnaire For 12 Years And Older (Aqlq(S)+12) And The Asthma Control Questionnaire (Acq-6)
2015
-
Acute And Chronic Impact Of Cardiovascular Events On Health State Utilities
2014
-
Concomitant Use of Non-Steroidal Anti-Inflammatory Drugs (Nsaids) And Proton Pump Inhibitors (Ppis) in Newly Diagnosed Patients With Osteoarthritis (Oa), Rheumatoid Arthritis (Ra) or Ankylosing Spondylitis (As)
2014
-
A systematic review of methodological frameworks for evaluation of ethical considerations in health technology assessment
2014
-
An Examination Of Disparity In Access To Mental Health Services Among People Living With Human Immunodeficiency Virus (Hiv) And Co-Morbid Depression In Ontario
2014
-
Budget Impact Analysis Of Dolutegravir In The Treatment Of Human Immunodeficiency Virus (Hiv) In Ontario, Canada
2014
-
Burden of illness of diabetic foot ulcers in Canada
2014
-
Comparative efficacy and safety of golimumab, infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis: A bayesian indirect treatment comparison meta-analysis
2014
-
Cost-Utility Analysis of Newer HER2- Testing Technologies to Target Trastuzumab in the Adjuvant Breast Cancer Setting
2014
-
Cost-Utility Analysis of Practice Deviations From Guidelines in HER2-Targeted Testing and Treatment for Breast Cancer
2014
-
Cost-effectiveness of golimumab versus infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis
2014
-
Cost–Effectiveness Analysis Parallel to a Randomized Controlled Trial Comparing Vertical Scar Reduction (VSR) and Inverted T-Shaped Reduction (ITR) Mammoplasty
2014
-
EQ-5D health utilities are estimated subject to considerable uncertainty
2014
-
Evaluation Of A Chronic Disease Management System For The Treatment And Management Of Diabetes In Primary Health Care Practices In Ontario
2014
-
Factors associated with large increases in self-reported health status in infliximab-treated inflammatory bowel disease patients: results from the bioadvance survey
2014
-
Follow-Up Of Psychoactive Drug Use In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada)
2014
-
Health Care Resource Utilization in the Management of Chronic Lymphocytic Leukemia at an Ontario Cancer Centre
2014
-
Health State Utilities Associated With Attributes Of Treatments For Hepatitis C
2014
-
Increased In Acute Health Care Use Among People Living With Human Immunodeficiency Virus (Hiv) And Co-Morbid Depression In Ontario: A Longitudinal Study
2014
-
Mammographic Density in Association with Smoking Status and Smoking Histories in a Sample of Postmenopausal Women: Results From a Cross-Sectional Study
2014
-
Prevalence And Incidence Of Interstitial Pulmonary Diseases With Fibrosis
2014
-
Psychiatric Health Care Utilisation And Related Costs In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada)
2014
-
Real World Drug Utilization Of Hiv Therapies In Canada
2014
-
Respiratory Syncytial Virus Prophylaxis In Down Syndrome: A Prospective Cohort Study
2014
-
Screening For Type 2 Diabetes: A Methodological Review And Cost Analysis
2014
-
Some statistical considerations in estimating a disease progression model for chronic obstructive pulmonary disease (COPD)
2014
-
Survival crossover adjustment and cost effectiveness analysis: An empirical and methodological review with application
2014
-
The Canadian Eq-5d Valuation Study: Estimating Time Trade-Off Values For The Eq-5d-5l
2014
-
The Cost-Effectiveness of 2nd Line Crizotinib in EML4-Alk Rearranged Advanced NSCLC in Ontario
2014
-
Time trade-off utility assessment with a 10-year time horizon: when should alternative approaches be considered?
2014
-
Use Of Economic Evidence To Inform Drug Reimbursement Decision Making: The Case For Ontario
2014
-
Adherence Interventions to Improve Adherence to Antiretroviral Therapy in Low Income Settings: An Individual Patient Data Network Meta-Analysis
2013
-
Assessment of a Canadian Primary Care Electronic Medical Record Database for Use in Observational Studies
2013
-
Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)
2013
-
Development of an Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA) for 6-10 Year Old Patients in 11 Languages
2013
-
Easing Decision-Making by Expanding Methods of Multiple Treatment Comparison Meta-Analysis – Incorporating Non-Comparative Studies Via Informative Priors
2013
-
Factors Associated with Compliance with Palivizumab Prophylaxis in the Canadian RSV Evaluation Study for Synagis (CARESS) Registry (2005-2012)
2013
-
Health Utilities Index (Hui®): Population Reference Statistics
2013
-
Impact of Major Clinical Events on Utilities in the Context of Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) Treated with Dialysis
2013
-
Measuring Pros That Matter to Bariatric and Body Contouring Surgery: The Body-Q
2013
-
Modeling a Switch from Trivalent to Quadrivalent Influenza Vaccine in Canada and the United Kingdom
2013
-
Multinational Consistency of a Discrete Choice Model in Quantifying Health States for the Extended 5-Level EQ-5D
2013
-
Psychoactive Drug Use, Polypharmacy and Co-Morbidities in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec
2013
-
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATION IN INFANTS WITH CONGENITAL AIRWAY ANOMALIES IN THE CANADIAN REGISTRY OF SYNAGIS (R) (CARESS) FOLLOWING PROPHYLAXIS (2005-2012)
2013
-
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATIONS IN THE CANADIAN REGISTRY FOR SYNAGIS (CARESS)
2013
-
A cost-minimization analysis of a new fixed-dose combination of dutasteride and tamsulosin compared to concomitant administration of both monotherapies for the treatment of symptomatic benign prostatic hyperplasia in Quebec, Canada
2013
-
Are canadians different from americans in stated preferences for health? valuing EQ-5D-5L health states using discrete choice experiments
2013
-
CAN INDIVIDUAL HEALTH TECHNOLOGIES IMPROVE OVERALL CHRONIC DISEASE MANAGEMENT?
2013
-
COMPARING EQ-5D VALUATION STUDIES: A SYSTEMATIC REVIEW AND METHODOLOGICAL REPORTING CHECKLIST
2013
-
Cost-Effectiveness Of Eml4-Alk Fusion Testing In Combination With Crizotinib Treatment For Patients With Advanced Non-Small Cell Lung Cancer Living In Ontario
2013
-
Cost-effectiveness of ticagrelor versus generic clopidogrel in patients with acute coronary syndromes in Canada
2013
-
Costs and health care resource utilization associated with asthma in canada: A systematic review
2013
-
DEVELOPMENT OF THE 6-10 YEAR INTERVIEWER-ADMINISTERED VERSION OF THE ASTHMA CONTROL QUESTIONNAIRE (ACQ-IA) IN SPANISH FOR GUATEMALA AND PERU
2013
-
Excite – A New Collaborative Model Of Pre-Market Evaluation Of Health Technologies
2013
-
HEALTH UTILITIES INDEX (R) : EXTENDING THE AGE RANGE TO PRE-SCHOOLERS
2013
-
Harmonization Of Health Technology Assessement And Regulatory Processes And Evidentiary Requirements For Drugs And Devices: Opportunities And Challenges
2013
-
How can we use discrete event simulation to improve access to health care: an assessment of increasing access to care for children with medically refractory epilepsy
2013
-
Impact of multiple treatment comparison meta-analysis on value of information evaluations: a case study of pharmacotherapies for chronic obstructive pulmonary diseases
2013
-
Modelling drug class effects in bayesian multiple treatment comparison meta-analysis: Applications in early and advanced parkinson's disease
2013
-
Psychometric Development Of A New Pro Instrument: The Face-Q Scales For Facelift Patients
2013
-
Reliability and validity of current perception threshold test in mechanical neck disorder
2013
-
Responsiveness Of The Face-Q: A New Pro For Facial Aesthetic Paitents
2013
-
Rsv Hospitalization In Infants With Neuromuscular Disease In The Canadian Registry Of Synagis® (Caress) Following Prophylaxis (2005-2012)
2013
-
Systematic review of cost-effectiveness analyses of dabigatran versus warfarin for atrial fibrillation across different health care systems
2013
-
The effects of excluding treatments from network meta-analysis
2013
-
Underestimation of uncertainties in health utilities dervied from mapping algorithms involving health-related quality of life measures: statistical explanations and potential remedies
2013
-
Valuing EQ-5D-5L: Can latent utilities derived from a discrete choice model be transformed to health utilities derived from time trade-off tasks?
2013
-
Why are the findings of cost-effectiveness analyses of biologic treatment for rheumatoid arthritis so different?
2013
-
Why are the findings of indirect comparisons of boceprevir and telaprevir for hepatitis C infection different? A methodological review
2013
-
CHARACTERISTICS OF THE ABORIGINAL PEOPLE WITH DIABETES IN THE SOUTH-WESTERN OF ONTARIO, CANADA
2012
-
CL3 Calibrating Bayesian Multiple Treatment Comparison Meta-Analysis With Multiple Cost-Effectiveness Acceptability Curves
2012
-
PCN110 Differences in Health-Related Quality of Life Between Children Treated for Acute Lymphoblastic Leukemia (ALL) on Dana Farber Cancer Institute (DFCI) Protocols
2012
-
PDB34 Economic Evaluation of Treating Diabetes Patients According to Guidelines in South-Western Ontario, Canada
2012
-
PDB77 Characteristics of Patients With Diabetes in Southwestern Ontario, Canada
2012
-
PHP174 Physical Activity Matters: The Associations Between Body Mass Index, Physical Activity and Health-Realted Quality-of-Life Trajectories Over 10 Years
2012
-
PHP202 Bridging the Gap Between Institutional Levels Using Systems Analysis
2012
-
PMS6 Anti-Tumour Necrosis Factor (TNF) Drugs for the Treatment of Psoriatic Arthritis (PsA)
2012
-
PMS60 The Time Horizon Matters: Exploratory Results Varying the Time Horizon in Time Trade-Off and Standard Gamble Utility Elicitation
2012
-
PRM148 Sample Size and Power Considerations in Network Meta-Analysis
2012
-
PRM6 Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis
2012
-
PRS39 Preference and Willingness to Pay for a Treatment of Pulmonary Arterial Hypertension
2012
-
PSU11 Medical Costs Comparison Between Internal Fixation and Arthoplasty in Patients With Hip Femoral Neck Fractures
2012
-
EMPIRICAL EXAMINATION OF STARTING POINT BIAS WITH THE BIDDING GAME IN A WILLINGNESS-TO-PAY ANALYSIS
2012
-
MO4 Economic Evaluation of Treatment Strategies for Late-Presentation Acute Ischemic Stroke
2012
-
PCV5 Intra-Arterial Thrombolysis Versus Standard Treatment or Intravenous Thrombolysis in Adults with Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
2012
-
PIH12 Budget Impact Analysis of Adding a New Fixed-Dose Combination Therapy of Dutasteride and Tamsulosin to the Treatment of Symptomatic Benign Prostatic Hyperplasia in Quebec, Canada
2012
-
PIH16 Cost-Effectiveness of a New Fixed-Dose Combination of Dutasteride and Tamsulosin for the Treatment of Symptomatic Benign Prostatic Hyperplasia in Quebec, Canada
2012
-
PIH39 Eliciting Preferences to the EQ-5D-5L Health States: Discrete Choice Experiment or Multiprofile Case of Best-Worst Scaling
2012
-
PIH56 Measuring Quality of Life in Facial Aesthetic Patients: Field-Testing of a New Modular System (the FACE-Q)
2012
-
PIN30 Economic Evaluation of a Cluster Randomized Controlled Trial of an Influenza Immunization Program Directed at Healthy Children
2012
-
PMD25 Comparison of Statistical Methods Used to Model Health Care Costs by Dialysis Modality in the Treatment of Kidney Failure
2012
-
PMD3 Does Current Perception Threshold Test Can Differentiate Categories of Mechanical Neck Disorder?
2012
-
PMD8 Efficacy of Systemic Hyperbaric Oxygen Therapy for Non-Healing Diabetic Ulcers of the Lower Limb: Systematic Review and Meta-Analysis
2012
-
PMS85 Why the Findings of Published Rheumatoid Arthritis Multiple Treatment Comparisons are So Different - An Overview of Recurrent Methodological Shortcomings
2012
-
PMS90 the Influence of ‘Weak Links' on Comparative Treatment Effects in Multiple Treatment Comparison Meta-Analysis: A Simulation Study
2012
-
PRM28 Physicians as Pseudo-Agents in a Hospital Emergency Department Discrete Event Simulation
2012
-
PRS52 The Stability of Additive Treatment Effects in Multiple Treatment Comparison Meta-Analysis: a Simulation Study
2012
-
PSY65 Meta-Analysis of Health-Related Quality of Life Outcomes – Methods for Enhancing Interpretability of Findings
2012
-
A COMPARATIVE STUDY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS IN PREMATURE INFANTS
2011
-
CARESS: THE CANADIAN REGISTRY OF SYNAGIS (2005-2010)
2011
-
PCN112 Cost-Utility of Treatment for Acute Lymphoblastic Leukemia (ALL) in Childhood
2011
-
PCN127 Health State Utility Assessment for Breast Cancer
2011
-
PCN175 Reimbursement of Anticancer Drugs in Canada: What Can We Learn from the Nice New Appraisal Process for Life-Extending End-of-Life Treatments?
2011
-
PCV110 Health-Related Quality of Life After Venous Thromboembolism
2011
-
PCV50 Hospital Costs Associated with Atrial Fibrillation in Canada
2011
-
PHP158 Determining the Monetary Value of a Quality-Adjusted Life Year (QALY): Systematic Review of the Evidence
2011
-
PIH27 Potential Health and Economic Impact of Adding Rotarixtm to Routine Infant Vaccination Programs in Canada
2011
-
PMD34 Cost Effectivness of Ambulatory Cardiac Monitor versus Holter
2011
-
PMD86 A Systematic Review of Economic Evaluations Conducted for Assessment of Genetic Testing Technologies
2011
-
PMH26 Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte-Carlo Markov Model
2011
-
PMS22 The Burden of Illness of Osteoporosis in Canada
2011
-
PSY41 Health Status and Health-Related Quality of Life Reported by Females with Bleeding Disorders from the Canadian National Haemophilia Registry
2011
-
RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS IN SPECIAL POPULATIONS
2011
-
RESPIRATORY SYNCYTIAL VIRUS HOSPITALIZATIONS IN THE CANADIAN REGISTRY FOR SYNAGIS (CARESS)
2011
-
PDB76 DESIGNING A SERVICE FRAMEWORK FOR ELECTRONIC PERSONAL HEALTH RECORDS: A PATIENT-CENTRED APPROACH
2011
-
PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS: A CANADIAN COST EFFECTIVENESS ANALYSIS
2011
-
PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO
2011
-
PMD25 THE COST-UTILITY AND VALUE OF INFORMATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION COMPARED TO STANDARD MANAGEMENT AND SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC VALVE STENOSIS
2011
-
PRM29 METHODOLOGICAL DIFFERENCES IN EQ-5D SCORING SYSTEMS: A SYSTEMATIC REVIEW AND ANALYSIS
2011
-
PSY23 ECONOMIC EVALUATION OF ERYTHROPOIESIS STIMULATING AGENTS IN CRITICALLY ILL TRAUMA PATIENTS
2011
-
PSY48 A WORKPLACE HEALTH PROGRAM FOR BRITISH COLUMBIA PUBLIC SERVICE AGENCY (CANADA)
2011
-
PUK6 LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
2011
-
CARESS: THE CANADIAN REGISTRY OF SYNAGIS (2006-2009)
2010
-
PDB35 COST-CONSEQUENCE ANALYSIS OF CSII VS. MDI:A CANADIAN PERSPECTIVE
2010
-
PMC31 CONSTRUCTION OF PRIMARY HUI3 PERSON-MEAN UTILITY SCORING FUNCTION
2010
-
PMS21 THE ACUTE CARE COSTS OF OSTEOPOROSIS-RELATED FRACTURES IN CANADA
2010
-
PRS42 EFFECTS OF ASTHMA MANAGEMENT, SOCIOECONOMIC STATUS AND MEDICATION INSURANCE CHARACTERISTICS ON EXACERBATION FREQUENCY IN CHILDREN WITH ASTHMA
2010
-
RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN SPECIAL POPULATIONS
2010
-
HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO
2010
-
PCN143 COST-EFFECTIVENESS OBSERVATIONS AND ONCOLOGY DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE JOINT ONCOLOGY DRUG REVIEW
2010
-
PCN31 COST COMPARISON OF INPATIENT AND OUTPATIENT HOSPITALBASED SERVICES BETWEEN TWO STRATEGIES FOR TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN A PUBLICLY FUNDED HEALTH CARE SYSTEM
2010
-
PGI26 CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR REFRACTORY CROHN'S DISEASE
2010
-
PIN14 REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COST-CONSEQUENCE ANALYSIS OF A 7-, 10-AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CANADA
2010
-
PMS74 USE OF A DISEASE-SPECIFIC INSTRUMENT IN ECONOMIC EVALUATIONS: MAPPING WOMAC ONTO THE EQ-5D UTILITY INDEX
2010
-
PR4 ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION: COMPARING A REPEATED MEASURES DESIGN AND LATENT GROWTH MODELING
2010
-
PRS7 TRIPLE THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
2010
-
PSY30 COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES VERSUS NO TREATMENT FOR MORBID OBESITY
2010
-
UT3 RELIABILITY OF HEALTH UTILITIES INDEX (HUI) SCORES: PATIENT AND PARENT INTER-RATER AGREEMENT ACROSS TWO CLINICAL TRIALS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD
2010
-
UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO
2010
-
DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES
2009
-
MC6 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION
2009
-
MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R
2009
-
PCN130 HEALTH UTILITIES OF CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN DFCI 95-01 RANDOMIZED CLINICAL TRIAL
2009
-
PCN31 A DESCRIPTIVE ANALYSIS OF THE ASSOCIATION BETWEEN BREAST CANCER RISK, BONE MINERAL DENSITY AND FRACTURES IN POST-MENOPAUSAL WOMEN IN THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY
2009
-
PCV110 COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY
2009
-
PDB21 WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS
2009
-
PG14 SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE
2009
-
PHP80 CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS: A SYSTEMATIC REVIEW
2009
-
PIN33 POTENTIAL HEALTH AND ECONOMIC IMPACT OF NEW PNEUMOCOCCAL VACCINES IN CANADA: A MARKOV MODELLING APPROACH
2009
-
PIN8 BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA
2009
-
PMC35 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION
2009
-
PMH18 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE
2009
-
PMH2 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE
2009
-
PND31 HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL MODERATE ALZHEIMER'S DISEASE HEALTH STATE: A CANADIAN SURVEY OF THE GENERAL PUBLIC
2009
-
PND46 A SYSTEMATIC REVIEW AND META-ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF CIDP
2009
-
PND47 ASSESSING CANADIANS' WILLINGNESS-TO-PAY FOR ALZHEIMER'S DISEASE MEDICATIONS
2009
-
PND48 SUPPORT FOR PROVIDING UNRESTRICTED ACCESS TO AN ALZHEIMER'S DISEASE MEDICATION IN CANADA: RESULTS FROM A STUDY OF THE GENERAL POPULATION
2009
-
PSY18 THE BURDEN OF OBESITY IN ONTARIO
2009
-
PSY30 COST-UTILITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) COMPARED WITH CORTICOSTEROIDS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IN CANADA
2009
-
PSY38 ELICITING HEALTH STATE UTILITIES FOR IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA: RESULTS OF A GENERAL PUBLIC BASED TIME TRADE-OFF SURVEY
2009
-
PSY42 BLEEDING DISORDERS, MENORRHAGIA AND IRON DEFICIENCY: AN EXAMINATION OF QUALITY OF LIFE
2009
-
HT2 HEALTH TECHNOLOGY ASSESSMENT – A COMPREHENSIVE FRAMEWORK FOR EVIDENCE-BASED RECOMMENDATIONS IN ONTARIO
2009
-
PCN68 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA
2009
-
PGI6 COST EFFECTIVENESS ANALYSIS OF ANTI-TNF-ALPHA; DRUGS FOR REFRACTORY ULCERATIVE COLITIS
2009
-
PIH11 ECONOMIC EVALUATION ALONGSIDE THE CAFFEINE FOR APNEA OF PREMATURITY (CAP) TRIAL: SHORT TERM OUTCOMES
2009
-
PIH56 CARESS: THE CANADIAN REGISTRY OF SYNAGIS, SUMMARY OF 2006–2008 RSV SEASONS
2009
-
PIH9 A SIMULATION MODELING OF THE EFFECT OF DOSING SCHEDULE ON THE BENEFIT AND COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION IN CANADA
2009
-
PMC62 ASSESSING THE QUALITY OF CONJOINT ANALYSIS APPLICATIONS IN HEALTH: A PILOT EVALUATION OF THE ISPOR CHECKLIST FOR GOOD RESEARCH PRACTICE IN CONJOINT ANALYSIS
2009
-
PMS43 IS THE HEALTH UTILITIES INDEX VALID AND RESPONSIVE IN ASSESSING PATIENTS WITH ANKYLOSING SPONDYLITIS?
2009
-
PMS45 EXTENSION FROM INPATIENTS TO OUTPATIENTS: PERFORMANCE OF THE OXFORD KNEE SCORE IN MEASURING HEALTH OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS
2009
-
PND26 UTILITIES FOR MODERATE ALZHEIMER'S DISEASE: RESULTS FROM A SURVEY OF THE GENERAL PUBLIC IN CANADA
2009
-
PSS2 DISTRIBUTION OF PATHOGENS ASSOCIATED WITH ACUTE OTITIS MEDIA: A SYSTEMATIC REVIEW OF THE LITERATURE
2009
-
PSS9 REDUCTION OF ACUTE OTITIS MEDIA IN CHILDREN: A COSTCONSEQUENCE ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) COMPARED WITH THE 7-VALENT PNEUMOCOCCAL VACCINE (PCV-7)
2009
-
PSY9 USING UTILIZATION RECORDS TO ESTIMATE THE BURDEN OF OBESITY IN ADULTS LIVING IN ONTARIO
2009
-
QL3 ESTIMATION OF UTILITY VALUES FOR DIABETESXD-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA
2009
-
VA2 COST EFFECTIVENESS ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN CANADA
2009
-
CASE2 DOTECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?: FINDINGS FROM, AND IMPLICATIONS OF, ONTARIO'S EVIDENCE-BASED HTA PROCESS
2008
-
PCV93 FACTORS DETERMINING UTILITY MEASURED WITHTHE EQ-5D IN PATIENTS WITH A TRIAL FIBRILLATION
2008
-
PMC60 CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST: ODDS SOLUTION TO RELATIVE RISK FALLACIES
2008
-
PRS21 CAN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) DATA FROM DIFFERENT COUNTRIES BE COMBINED FOR ANALYSES?
2008
-
PRS22 ARE THE MEASUREMENT PROPERTIES OF THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT ACROSS LANGUAGES?
2008
-
CASE 2 DRUG ELUTING STENTS—AN EXAMPLE OFTHETRANSITION FROM EVIDENCETO POLICYTHROUGHTHE ONTARIO COMPREHENSIVE APPROACHTOTHE DIFFUSION OF HEALTHTECHNOLOGIES
2008
-
DH3 THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL: A PATIENT-LEVEL APPROACH USING QUEBEC'S PROVINCIAL HEALTH PLAN DATA
2008
-
OM2 USINGVALUE OF INFORMATION METHODOLOGYTO DETERMINE THE SAMPLE SIZE FOR A RANDOMIZED CLINICAL TRIAL FROM AN INDUSTRY PERSPECTIVE
2008
-
PCN72 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE IN LONG-TERM SURVIVORS OF CANCER IN CHILDHOOD IN BRAZIL: AN ASSESSMENT OF THE CONSTRUCT VALIDITY OF THE HEALTH UTILITIES INDEX (HUI3)
2008
-
PCN73 COMPARISON OF SURVIVAL QUALITY FROM TWO TREATMENT STRATEGIES FORACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD: DANA-FARBER CANCER INSTITUTE (DFCI) AND BERLIN-FRANKFURT-MONSTER (BFM)
2008
-
PCV12 METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM OF WARFARIN
2008
-
PCV53 DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE: COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA
2008
-
PCV67 RESPONSIVENESS OF PROXY-RATED PREFERENCE-BASED MEASURES OF HEALTH-RELATED QUALITY OF LIFE
2008
-
PGI7 COST EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI SCREENING IN PREVENTION OF GASTRIC CANCER IN CHINESE
2008
-
PHP25 TOWARD HIGH PERFORMANCE ‘PHARMACARE’ SYSTEMS: A REVIEW OF EXPERIENCES IN SEVEN COUNTRIES
2008
-
PHP74 THE CADTH GUIDELINES FORTHE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST?
2008
-
PIH11 IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIALVIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
2008
-
PIH22 CARESS: THE CANADIAN REGISTRY OF SYNAGIS(®)
2008
-
PM3 THEVALIDITY AND RELIABILITY OF A PARENT-CHILD DYAD APPROACHTO UTILITY AND QUALITY-OF-LIFE ASSESSMENT IN CHILDREN
2008
-
PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS
2008
-
PMH65 EFFECT OF PRIOR AUTHORIZATION ON ANTIPSYCHOTIC DRUG USE IN LONG-TERM CARE: POPULATION-BASED NATURAL EXPERIMENT
2008
-
PMS34 ATWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTERTOTAL KNEE REPLACEMENT
2008
-
PMS7 TREATMENT OF DISPLACED FEMORAL NECK FRACTURES IN THE ELDERLYA COST BENEFIT ANALYSIS
2008
-
PR1 VARIABILITY OF HEALTH UTILITIES INDEX MARK 3 (HUI3) MEASUREMENTS DURINGTREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
2008
-
PAR32 INVESTIGATION OF RESPONSE SHIFT IN HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS UNDERGOINGTOTAL KNEE REPLACEMENT
2007
-
PCN76 COMPARISON OF PHYSICIAN AND PATIENT PREFERENCES FOR COLORECTAL CANCER SCREENING USING A DISCRETE CHOICE EXPERIMENT
2007
-
PCN45 A PRACTICAL AND USEFUL COMBINATION OF MEASURES FOR ASSESSING THE COST-UTILITY OF TWO MAJOR TREATMENT STRATEGIES FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD: RESOURCE INTENSITY WEIGHTS (RIWS) AND THE HEALTH UTILITIES INDEX (HUI)
2007
-
PND27 DETECTION OF DIFFERENTIAL ITEM FUNCTIONING BETWEEN ENGLISH AND CHINESE VERSIONS OF THE PDQ-8
2007
-
PST3 THE IMPACT OF WIDESPREAD ACCESS TO ORGANIZED STROKE CARE IN CANADA
2007
-
PAR11 ARE THEY MEASURABLE? A STUDY ON ELICITING INDIRECT AND INTANGIBLE COSTS OF KNEE OSTEOARTHRITIS USING HUMAN CAPITAL APPROACH AND WILLINGNESS-TO-PAY IN MULTIETHNIC ASIAN POPULATION IN SINGAPORE
2006
-
PCN70 RELIABILITY AND VALIDITY OF HEALTH UTILITIES INDEX (HUI) SCORES FOR SURVIVORS OF BRAIN TUMORS IN CHILDHOOD: AGREEMENT BETWEEN PATIENTS AND PARENTS
2006
-
PCV55 ECONOMIC EVALUATION OF DRUG ELUTING STENTS: COST-UTILITY ANALYSIS
2006
-
PCV77 DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS
2006
-
PMH11 RATIONAL CHOICE OF TREATMENT STRATEGY IN MODERATE TO SEVERE ALZHEIMER'S DISEASE PATIENTS LIVING IN CANADA
2006
-
PRS13 USING PATIENT DESCRIPTORS TO DEVELOP A PRO MEASUREMENT STRATEGY FOR CLINICAL TRIALS: EVALUATING THE COPD PATIENT'S EXPERIENCE OF DYSPNEA
2006
-
PRS16 MEASURING THE IMPACT OF COPD ON PATIIENTS' LIVES IN AN INTERNATIONAL STUDY
2006
-
CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA
2006
-
PAR15 PRELIMINARY INVESTIGATION OF THE DISCRIMINATORY CAPACITY OF MEASURES OF LOW INTENSITY SYMPTOM STATE-ATTAINMENT USING THE WOMAC PAIN SUBSCALE SCORE IN PATIENTS TREATED WITH HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS
2006
-
PAS3 ECONOMIC EVALUATION OF SYMBICORT® (BUDESONIDE/FORMOTEROL) SINGLE-INHALER MAINTENANCE AND RELIEVERTHERAPY (SMART) IN ASTHMA
2006
-
PCN26 INTER-RATERAGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD: PARENT VERSUS CLINICIAN ASSESSMENT
2006
-
PCN27 HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS
2006
-
PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES: RESULTS FROM A COMPUTERIZED SIMULATION MODEL
2006
-
PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS: RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY
2006
-
PEY8 ECONOMIC EVALUATION OF EARLY TREATMENT FOR PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA
2006
-
PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS: CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER?
2006
-
PMC13 APPLYING EXPECTANCY-VALUE MODEL TO UNDERSTAND HEALTH PREFERENCE-AN EXPLORATORY STUDY
2006
-
PSU1 COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA)
2006
-
PAR10 ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH CORE SETS FOR OSTEOARTHRITIS FROM THE PERSPECTIVE OF PATIENTS WITH KNEE OSTEOARTHRITIS IN SINGAPORE
2005
-
PAR16 POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE COST-EFFECTIVENESS: RESULTS FROM AN ANALYSIS OF ETANERCEPT USE IN RHEUMATOID ARTHRITIS
2005
-
PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
2005
-
PDB57 TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGYWITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES: THE CANADIAN INSIGHT STUDY
2005
-
PMD1 COST ANALYSIS OF MANAGEMENT STRATEGIES FOR CLOSED AND OPEN GRADE ITIBIAL SHAFT FRACTURES
2005
-
PMH42 COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE: A NATURALISTIC STUDY
2005
-
PST10 THE METHODOLOGY BEHIND A PROSPECTIVE, OBSERVATIONAL STUDY OF THE ECONOMIC BURDEN OF ISCHEMIC STROKE
2005
-
PCN23 RELIABILITY OF SPANISH-LANGUAGE HUI MEASUREMENTS IN SURVIVORS OF CANCER IN CHILDHOOD:AGREEMENT BETWEEN PATIENTS, PARENTS, AND PHYSICIANS
2005
-
PCN25 RELIABILITY AND VALIDITY OF BRAZILIAN PORTUGUESE HEALTH UTILITIES INDEX (HUI) QUESTIONNAIRES FOR ASSESSING THE HEALTH STATUS OF SURVIVORS OF CHILDHOOD CANCER
2005
-
PCV26 THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY
2004
-
PCV4 FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION
2004
-
PIN26 VALIDATION OF 5-ITEM INSTRUMENT FOR ASSESSING SYMPTOM SEVERITY IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
2004
-
PCN22 THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE (EORTC QLQ-C30): VALIDATION OF ENGLISH VERSION IN SINGAPORE
2004
-
PCN26 ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION USING A REPEATED MEASURES DESIGN
2004
-
PGI9 RESPONSIVENESS TO CHANGE AND ENGLISH LANGUAGE VALIDATION OF THE WPAI-GERD QUESTIONNAIRE-RESULTS FROM A CANADIAN STUDY
2004
-
SC1 PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC) SCREENING STRATEGIES
2004
-
CE1 COST-EFFECTIVENESS MODEL OF RECOMBINANT HUMAN CHORIONIC GONADOTROPIN (R-HCG) VERSUS URINARY HCG (U-HCG) FOR ASSISTED REPRODUCTIVE TECHNIQUES (ART) IN THE USA
2003
-
Quality of life (QOL) differentiation analysis in patients undergoing controlled ovarian stimulation (COS) with two different preparations of recombinant human follicle-stimulating hormone (r-hFSH)
2003
-
PCHI5: AGREEMENT OF HEALTH UTILITIES INDEX SCORES AMONG SURVIVORS OF CANCER IN CHILDHOOD THEIR PARENTS AND THEIR DOCTORS IN URUGUAY
2003
-
PGS6: THE COST-EFFECTIVENESS OF ALTERNATIVE STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH UNINVESTIGATED DYSPEPSIA (UD): COMPARING THE CANDYS APPROACH TO EMPIRICAL ANTISECRETORY THERAPY AND PROMPT ENDOSCOPY
2003
-
PIN6: IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC RESISTANCE
2003
-
PIN9: IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC USE AND EXPENDITURES
2003
-
Is there any relationship between compliance and HRQoL in patients with heart failure?
2002
-
PCV37 DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE?
2002
-
PCV47 THE ASSESSMENT OF THE INFLUENCE OF AN EDUCATIONAL INTERVENTION ON PATIENT IMPORTANT OUTCOMES INCLUDING HEALTH RELATED QUALITY OF LIFE (HRQOL) AND MORTALITY USING A TIME-TO-EVENT SURVIVAL ANALYSIS IN PATIENTS WITH HEART FAILURE
2002
-
The impact of an educational intervention on multiple health realted quality of life measures in patients with heart failure (HF)
2002
-
Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach.
26:1721-1729.
2023
-
Whose Time Trade-Off Should Be Used? Anchoring Discrete Choice Experiment Latent Utilities in Health State Valuation.
26:1405-1412.
2023
-
Resurrecting Multiattribute Utility Function: Developing a Value Set for Health Utility for Glaucoma.
26:1249-1257.
2023
-
P31 The Association between Patient- and Caregiver-Reported Utility Values in Duchenne Muscular Dystrophy (DMD).
26:S7-S7.
2023
-
PCR230 Estimating Utility Values Using the Duchenne Muscular Dystrophy-Quality of Life Measure (DMD-QOL): A New Preference-Based Measure for Duchenne Muscular Dystrophy.
26:S355-S355.
2023
-
Modeling Tiered Pricing Frameworks: A Simulation Approach.
26:351-358.
2023
-
Generic Health-Related Quality of Life Utility Measure for Preschool Children (Health Utilities Preschool): Design, Development, and Properties.
26:251-260.
2023
-
CO107 Clinical Outcomes of Patients With Metastatic Renal Cell Carcinoma (MRCC) With or Without Sarcomatoid Differentiation Treated With Systemic Therapy in Real-World Canadian Setting.
25:S39-S39.
2022
-
CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy.
25:S52-S52.
2022
-
EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants.
25:S137-S138.
2022
-
EE528 Resource Use and Costs Associated With Computerized Decision Support System for Managing Patients With Atrial Fibrillation.
25:S159-S160.
2022
-
EPH152 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A 10-Year Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics.
25:S220-S220.
2022
-
EPH192 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics.
25:S228-S228.
2022
-
EPH26 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics.
25:S196-S196.
2022
-
EPH46 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics.
25:S200-S200.
2022
-
EE214 Impact of Depression Relapse on Participant Quality of Life and Costs to the English NHS: Secondary Analysis from the Antler Study on Antidepressant Discontinuation in Well Patients in Primary Care.
25:S375-S375.
2022
-
EE476 Cost-Effectiveness of Emicizumab Prophylaxis in Patients with Hemophilia a without Inhibitors.
25:S428-S428.
2022
-
PCR105 The Impact of Key Health State Transitions on Health-Related Quality of Life (HRQOL) in Duchenne Muscular Dystrophy (DMD): A Qualitative Study.
25:S560-S561.
2022
-
PCR176 Time Trade-Off Utility Values for Health States Characterizing Progressive Muscular Degeneration in Duchenne Muscular Dystrophy (DMD).
25:S574-S574.
2022
-
The (Harsh) Reality of Real-World Data External Comparators for Health Technology Assessment.
25:1253-1256.
2022
-
Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.
25:869-886.
2022
-
Rasch Analysis of the Michigan Hand Questionnaire.
25:638-646.
2022
-
Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness.
25:178-184.
2022
-
What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks.
25:302-317.
2022
-
POSC37 Economic Cost of Treatment in Canada: A Multi-Centre, Retrospective Study.
25:S93-S93.
2022
-
POSC427 Platform Trials: A Path to Efficient Decision Making and Faster Drug Approvals for Health Technology Assessment Bodies.
25:S276-S276.
2022
-
SC3 The Drivers of Health State Utilities in Duchenne Muscular Dystrophy (DMD): A Study Using the Health Utilities Index Mark 3 (HUI3).
24:S240-S240.
2021
-
Economic Consequences of Adult Living Kidney Donation: A Systematic Review.
24:592-601.
2021
-
Engaging the Voices of Children: A Scoping Review of How Children and Adolescents Are Involved in the Development of Quality-of-Life–Related Measures.
24:556-567.
2021
-
Rasch Analysis of Patient- and Parent-Reported Outcome Measures in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate.
24:404-412.
2021
-
Acceptability and Validity of the EQ-5D in Patients Living With Dementia.
23:760-767.
2020
-
PNS18 IMPROVING THE APPLICATION OF PUBLISHED HEALTH UTILITIES IN COST-UTILITY ANALYSES: DEVELOPMENT OF THE HEALTH UTILITY APPLICATION TOOL (HAT).
23:S286-S287.
2020
-
Development of System Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada.
23:74-88.
2020
-
PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS.
22:S521-S521.
2019
-
PDB3 HETEROGENEITY IN RENAL COMPOSITE ENDPOINTS IN CARDIOVASCULAR OUTCOMES TRIALS IN TYPE 2 DIABETES (T2D).
22:S572-S572.
2019
-
PNS278 A REVIEW OF HEALTH TECHNOLOGY ASSESSMENT GUIDELINES ON THE APPROVAL OF BIOSIMILARS.
22:S810-S810.
2019
-
PRO67 UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW.
22:S853-S853.
2019
-
Parent Proxy Discrepancy Groups of Quality of Life in Childhood Epilepsy.
22:822-828.
2019
-
PMS52 REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA.
22:S248-S248.
2019
-
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
21:318-325.
2018
-
Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
20:644-650.
2017
-
Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
20:644-650.
2017
-
The Diagnosis of Urinary Tract Infection in Young Children (DUTY) Study Clinical Rule: Economic Evaluation.
20:556-566.
2017
-
A Cost-Effectiveness Analysis of Reverse Total Shoulder Arthroplasty versus Hemiarthroplasty for the Management of Complex Proximal Humeral Fractures in the Elderly.
20:404-411.
2017
-
Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report.
19:704-719.
2016
-
Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force.
19:300-315.
2016
-
A Discrete Choice Experiment (Dce) To Elicit Preferences For Attributes Of A Bedside Pharmacogenetic Test – Preliminary Results.
18:A399-A399.
2015
-
Heterogeneity in the Definition of Drug Induced Hypoglycemia in Clinical Trials: A Review.
18:A601-A601.
2015
-
Non-Comparative Trials To Supplement Network Meta-Analyses Using Arm-Specific Meta-Regression: An Application To Combination Therapies In Hiv.
18:A683-A684.
2015
-
Psychiatric Healthcare Utilization and Related Costs In Newly Diagnosed Individuals With Autism Spectrum Disorder (Asd) In Quebec (Canada).
18:A746-A747.
2015
-
The Use of Single-Arm Evidence In The Comparative Efficacy of Interferon-Free Antivirals for Treatment-Naïve Hepatitis C Genotype 1.
18:A576-A576.
2015
-
Use of Economic Evaluations of Health Technologies In Dutch Healthcare Decision-Making: Barriers And Facilitators.
18:A540-A540.
2015
-
Zrx Mcdm: A Fully Flexible Tool to Support The Local Adaptation of Multiple-Criteria Decision Criteria In Health Care.
18:A703-A703.
2015
-
An Assessment of the Association Between Rural Status and Health Service Resource Use Among Patients With Ankle Sprains in Ontario.
17:A388-A388.
2014
-
Comparative Efficacy and Safety of Empagliflozin with Other Anti-Diabetic Drugs for the Treatment of Patients with Type 2 Diabetes Mellitus Who are Failing Insulin.
17:A332-A333.
2014
-
Comparative Efficacy and Safety of Empagliflozin with Other Antidiabetic Drugs for the Third Line Treatment of Type 2 Diabetes Mellitus.
17:A333-A333.
2014
-
Comparative Efficacy and Safety of Empagliflozin with Other Oral Antidiabetic Drugs for the Second Line Treatment of Type 2 Diabetes Mellitus.
17:A333-A333.
2014
-
Comparative Efficacy of Umeclidinium Bromide Versus Other Long-Acting Anticholinergic Monotherapies as Treatments for Copd Patients.
17:A588-A589.
2014
-
Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients.
17:A595-A595.
2014
-
Cost-Effectiveness Analysis of Umeclidinium Bromide Compared to Tiotropium Bromide for Symptomatic Patients with COPD in the UK.
17:A595-A595.
2014
-
Economic Evaluation of Bevacizumab Versus Ranibizumab in Neovascular Age-Related Macular Degeneration in China.
17:A782-A782.
2014
-
Impact of Demographics on Health Preferences in China: An Exploratory Analysis of China EQ-5D-5L Valuation Study.
17:A753-A753.
2014
-
Incretin Therapy and Risk of Pancreatitis in Type 2 Diabetes Mellitus: Systematic Review of Randomized and Non-Randomized Studies.
17:A740-A741.
2014
-
The Costs of Diagnosis and Treatment of Ankle Sprains and Fractures, 1980-2013: A Systematic Review.
17:A377-A377.
2014
-
Validating A Model To Predict Disease Progression Outcomes In Patients With COPD.
17:A560-A561.
2014
-
Health Utility Scores in Alzheimer’s Disease: Differences Based on Calculation With American and Canadian Preference Weights.
17:77-83.
2014
-
Assessing the Value of Symptom Relief for Patients with Gastroesophageal Reflux Disease Treatment: Willingness to Pay Using a Discrete Choice Experiment.
16:588-598.
2013
-
Measuring the Quality of a Childhood Cancer Care Delivery System: Assessing Stakeholder Agreement.
16:639-646.
2013
-
Measuring the Quality of a Childhood Cancer Care Delivery System: Quality Indicator Development.
16:647-654.
2013
-
Health utilities index®: Extending the age range to pre-schoolers.
16:A35-A36.
2013
-
Core Domains for a Person-Focused Outcome Measurement System in Cancer (PROMS-Cancer Core) for Routine Care: A Scoping Review and Canadian Delphi Consensus.
16:76-87.
2013
-
Economic Appraisal of a Community-Wide Cardiovascular Health Awareness Program.
16:39-45.
2013
-
PDB14 Characteristics of the Aboriginal People with Diabetes in the South-Western of Ontario, Canada.
15:A495-A496.
2012
-
Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada.
15:894-906.
2012
-
Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada.
15:580-585.
2012
-
An Exploratory Study of Response Shift in Health-Related Quality of Life and Utility Assessment Among Patients with Osteoarthritis Undergoing Total Knee Replacement Surgery in a Tertiary Hospital in Singapore.
15:S72-S78.
2012
-
Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT) (vol 14, pg 450, 2011).
14:963-963.
2011
-
The Use of a Decision Board to Elicit Brazilian Patients' and Physicians' Preferences for Treatment: The Case of Lupus Nephritis.
14:S141-S146.
2011
-
Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT).
14:450-457.
2011
-
Cost-Effectiveness of Transdermal Nitroglycerin Use for Preterm Labor.
14:240-246.
2011
-
Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease: A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation.
14:263-273.
2011
-
Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?.
14:160-165.
2011
-
Erratum.
13:1065-1065.
2010
-
Functional Impairment and Disability across Mood States in Bipolar Disorder.
13:984-988.
2010
-
Use of a Disease-Specific Instrument in Economic Evaluations: Mapping WOMAC onto the EQ-5D Utility Index.
13:873-878.
2010
-
Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?.
13:487-494.
2010
-
Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario.
13:S8-S11.
2010
-
Contemporary Challenges in Deriving Summary Estimates of Comparative Effectiveness Using Meta-Analysis.
13:S15-S17.
2010
-
Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome.
13:411-417.
2010
-
PMS58 HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO.
13:A133-A133.
2010
-
PMS60 UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO.
13:A133-A134.
2010
-
Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature.
13:328-334.
2010
-
Effects of Mode and Order of Administration on Generic Health-Related Quality of Life Scores.
12:1035-1039.
2009
-
The Impact of Drug Vintage on Patient Survival: A Patient-Level Analysis Using Quebec's Provincial Health Plan Data.
12:847-856.
2009
-
Cost-Effectiveness of Drug-Eluting Stents in a US Medicare Setting: A Cost-Utility Analysis with 3-Year Clinical Follow-Up Data.
12:649-656.
2009
-
Validity of a Short Functioning Test (FAST) in Brazilian Outpatients with Bipolar Disorder.
12:624-627.
2009
-
A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada.
12:245-252.
2009
-
Comparing the Health Utilities Index Mark 3 (HUI3) with the Short Form-36 Preference-Based SF-6D in Chronic Kidney Disease.
12:340-345.
2009
-
QALYs: The Basics.
12:S5-S9.
2009
-
Assessing the Impact of Censoring of Costs and Effects on Health-Care Decision-Making: an Example Using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study.
11:365-375.
2008
-
Time and Expected Value of Sample Information Wait for No Patient.
11:522-526.
2008
-
Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip.
11:470-477.
2008
-
A Study on Indirect and Intangible Costs for Patients with Knee Osteoarthritis in Singapore.
11:S84-S90.
2008
-
Applying the Expectancy-Value Model to Understand Health Values.
11:S61-S68.
2008
-
The Association of Body Mass Index with Health-Related Quality of Life: An Exploratory Study in a Multiethnic Asian Population.
11:S105-S114.
2008
-
Validity, Feasibility and Acceptability of Time Trade-Off and Standard Gamble Assessments in Health Valuation Studies: A Study in a Multiethnic Asian Population in Singapore.
11:S3-S10.
2008
-
Measuring Patient Preferences for Colorectal Cancer Screening Using a Choice-Format Survey.
10:415-430.
2007
-
Assessing Differences in Utility Scores: A Comparison of Four Widely Used Preference-Based Instruments.
10:256-265.
2007
-
PAR3 PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT MODERATE TO SEVERE OSTEOARTHRITIS (OA) PAIN OF THE HIP/KNEE.
8:A24-A25.
2005
-
MS3 ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTIN®TABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE.
8:241-241.
2005
-
PMDI9: COMMUNITY OR PATIENT PREFERENCES FOR COST-UTILITY ANALYSES: DOES IT MATTER?.
6:298-298.
2003
-
Oseltamivir for Treatment of Influenza in Healthy Adults: Pooled Trial Evidence and Cost-Effectiveness Model for Canada.
6:116-125.
2003
-
PWM5 PRELIMINARY VALIDATION OF A NEW DISEASE-SPECIFIC UTILITY MEASURE FOR ERECTILE DYSFUNCTION.
5:588-588.
2002
-
Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn.
5:312-328.
2002
-
PHP50 HEALTH-RELATED QUALITY OF LIFE IN HEMOPHILIA AND VON WILLEBRAND's DISEASE: MEASUREMENT PROPERTIES OF THE HEALTH UTILITIES INDEX.
5:158-158.
2002
-
POD7: THE EF-VAS: A PREFERENCE-BASED SELFADMINISTRATION INSTRUMENT FOR ASSESSING THE IMPACT OF ERECTILE DYSFUNCTION (ED) AND ED TREATMENT.
4:468-469.
2001
-
PQP7: IS COMPLIANCE WITH DRUG TREATMENT CORRELATED WITH HEALTH RELATED QUALITY OF LIFE?.
4:179-179.
2001
-
A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs.
4:16-31.
2001
-
TPDM6: DETERMINING COST DRIVERS IN A COSTEFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER.
2:152-152.
1999
-
WMM2: ECONOMIC EVALUATION OF PROSPECTIVE MULTINATIONAL CLINICAL TRIALS: A MODELING APPROACH.
2:229-229.
1999
-
PCV10: A HEALTH ECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN BELGIUM.
2:27-27.
1999
-
MGA5 Health Utilities Index: Further Evidence of Responsiveness.
1:41-41.
1998
-
MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation: Canada.
1:41-42.
1998
-
UT2 Practical Applications of the Health Utilities Index.
1:93-93.
1998
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)